Inofab Health
A digital health platform solution for patients of Asthma, COPD or Cystic Fibrosis.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 Valuation: €0.0 | round | |
| investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
Related Content
Inofab Health is a digital health company specializing in respiratory care. The company develops and manufactures a digital respiratory health platform for chronic conditions such as asthma, COPD, and cystic fibrosis. This platform includes the world's first personal ultrasonic spirometer, allowing patients to conduct lung function tests at home.
Inofab Health's business model focuses on providing both hardware (the spirometers) and a software platform for patients and healthcare providers to monitor and manage respiratory conditions. The company was founded in 2014 in Ankara, Turkey, and has since been acquired, first by Carbon Health and subsequently by Clario in November 2023. This indicates a strategic focus on integrating its respiratory monitoring technology into broader clinical trial and healthcare platforms.
Keywords: respiratory care, digital health, spirometer, asthma, COPD, cystic fibrosis, remote patient monitoring, medical devices, health technology, clinical trials